AAOS Femoral Shaft Fractures Guideline Article II
AAOS Femoral Shaft Fractures Guideline Article II
AAOS Femoral Shaft Fractures Guideline Article II
718
practice standards demand that physicians use the best available evidence in their clinical decision making. To assist in this, the clinical
practice guideline consists of a series
of systematic reviews of the available
literature regarding the treatment of
pediatric diaphyseal femur fractures.
The systematic review includes evidence published from 1966 through
October 1, 2008, and demonstrates
the good evidence that exists, shows
where evidence is lacking, and pinpoints topics that future research
must target to improve the treatment
of children with isolated diaphyseal
femur fractures. AAOS staff and the
Pediatric Diaphyseal Femur Frac-
tures Physician work group systematically reviewed the available literature and subsequently wrote the
following recommendations based
on a rigorous, standardized process.
Musculoskeletal care is provided in
many different settings by many different providers. We created this
guideline as an educational tool to
guide qualified physicians through a
series of treatment decisions in an effort to improve the quality and efficiency of care. The guideline should
not be construed as including all
proper methods of care or as excluding methods of care reasonably directed to obtaining the same results.
The ultimate judgment regarding any
Dr. Kocher is Orthopaedic Surgeon, Department of Orthopaedics, Childrens Hospital, Boston, MA. Dr. Sink is Orthopaedic Surgeon,
Department of Orthopaedics, The Childrens Hospital, Aurora, CO. Dr. Blasier is Vice Chief, Department of Orthopaedic Surgery, Little
Rock, AR. Dr. Luhmann is Pediatric Orthopedic Surgeon, Department of Orthopaedic Surgery, St. Louis Childrens Hospital, St. Louis,
MO. Dr. Mehlman is Director, Musculoskeletal Outcomes Research, Childrens Hospital Medical Center, Cincinnati, OH. Dr. Scher is
Pediatric Orthopaedic Surgeon, Department of Pediatric Orthopaedics, Hospital for Special Surgery, New York, NY. Dr. Matheney is
Professor and Attending Physician, Department of Orthopaedic Surgery, Childrens Hospital, Boston. Dr. Sanders is Orthopaedic
Surgeon, Department of Orthopaedics and Rehabilitation, University of Rochester, Rochester, NY. Dr. Watters is Orthopaedic
Surgeon, Bone and Joint Clinic of Houston, Houston, TX. Dr. Goldberg is Chief, Skeletal Dysplasia Clinic, Childrens Hospital and
Regional Medical Center, Seattle, WA. Dr. Keith is Professor, Orthopaedics and Biomedical Engineering, and Chief, Hand Surgery
Service, MetroHealth Medical Center, Case Western Reserve University, Cleveland, OH. Dr. Haralson is Executive Director of
Medical Affairs, AAOS, Rosemont, IL. Dr. Turkelson is Director, Department of Research and Scientic Affairs, AAOS. Ms. Wies is
Manager, Clinical Practice Guidelines Unit, Department of Research and Scientic Affairs, AAOS. Mr. Sluka is Lead Research
Analyst, Clinical Practice Guidelines Unit, Department of Research and Scientic Affairs, AAOS. Ms. Hitchcock is Medical Research
Librarian, Department of Research and Scientic Affairs, AAOS.
Dr. Kocher or a member of his immediate family serves as a board member, owner, officer, or committee member of American
Orthopaedic Society for Sports Medicine and Pediatric Orthopaedic Society of North America; serves as a paid consultant to or is an
employee of Biomet, Smith & Nephew, Conmed Linvatec, Covidien, and OrthoPeditarics; and has received research or institutional
support from Conmed Linvaetec. Dr. Sink or a member of his immediate family serves as a board member, owner, officer, or
committee member of Pediatric Orthopaedic Society of North America and The Childrens Hospital Medical Board; serves as a
member of a speakers bureau or has made paid presentations on behalf of Biomet; and serves as an unpaid consultant to Biomet.
Dr. Blasier or a member of his immediate family is a member of a speakers bureau or has made paid presentations on behalf of
Synthes and has received research or institutional support from Synthes. Dr. Luhmann or a member of his immediate family is a
member of a speakers bureau or has made paid presentations on behalf of Medtronic Sofamor Danek and Stryker; serves as a paid
consultant to or is an employee of Medtronic Sofamor Danek and Stryker; and has received research or institutional support from
Medtronic Sofamor Danek and Stryker. Dr. Mehlman or a member of his immediate family serves as an unpaid consultant to Stryker;
has received research or institutional support from DePuy, Medtronic Sofamor Danek, the National Institutes of Health (NIAMS and
NICHD), Synthes, and the University of Cincinnati; and has stock or stock options held in Eli Lilly and Zimmer. Dr. Scher or a
member of his immediate family serves as a board member, owner, officer, or committee member of the American Academy for
Cerebral Palsy and Developmental Medicine and the Pediatric Orthopaedic Club of New York. Dr. Sanders or a member of his
immediate family has received research or institutional support from Medtronic Sofamor Danek and K2M, and has stock or stock
options held in Abbott and Biomedical Enterprises. Dr. Watters or a member of his immediate family serves as a board member,
owner, officer, or committee member of North American Spine Society, American Board of Spine Surgery, Board of Adviser Official
Disability Guidelines, and Med Center Ambulatory Surgery Center; is a member of a speakers bureau or has made paid
presentations on behalf of Stryker and Synthes; serves as a paid consultant to or is an employee of Orthox and Stryker; and has
stock or stock options held in Intrinsic Therapeutics. Dr. Haralson or a member of his immediate family serves as a paid consultant to
or is an employee of Medtronic and Medtronic Sofamor Danek, and has stock or stock options held in Orthox and AllMeds.
Ms. Wies or a member of her immediate family has stock or stock options held in Shering Plough. None of the following authors or a
member of their immediate families has received anything of value from or owns stock in a commercial company or institution related
directly or indirectly to the subject of this article: Dr. Matheney, Dr. Goldberg, Dr. Keith, Dr. Turkelson, Mr. Sluka, and Ms. Hitchcock.
719
Methods
The methods used to develop the
clinical practice guideline were designed to combat bias, enhance
transparency, and promote reproducibility. Their purpose is to allow interested readers the ability to inspect
all of the information the work
group used to reach all of its decisions and to verify that these decisions are in accord with the best
available evidence. The draft of the
guideline was subject to peer review
and public commentary, and it was
approved by the AAOS EvidenceBased Practice Committee; Guidelines and Technology Committee;
720
Grading the
Recommendations
Following data extraction and analyses, each guideline recommendation
was assigned a preliminary grade
that was based on the total body of
evidence available using the following system:
A: Good-quality evidence (more
than one level I study with consistent
findings for or against recommending intervention).
B: Fair-quality evidence (more than
one level II or III study with consistent findings or a single level I study
for or against recommending intervention).
C: Poor-quality evidence (more
than one level IV or V study or a single level II or III study for or against
recommending intervention).
I: No evidence or conflicting evidence (there is insufficient or
conflicting evidence not allowing a
recommendation for or against intervention).
Final grades were based on preliminary grades assigned by AAOS staff,
which took into account only the
quality and quantity of the available
evidence as listed above. Work group
members then modified the grade using the Form for Assigning Grade of
Recommendation (Interventions), as
listed above. This form, which is
based on recommendations of the
work group,4 requires the work
group to consider the harms, benefits, and critical outcomes associated
with a treatment. It also requires the
work group to evaluate the applica-
Guideline Language
Each recommendation was constructed using the following language, which took into account the
final grade of recommendation:
We recommend: grade A (level I).
We suggest: grade B (level II or III).
Option: grade C (level IV or V).
We are unable to recommend for
or against: grade I (no evidence or
conflicting evidence).
Recommendations
Recommendation 1
We recommend that children aged
<36 months with a diaphyseal femur
fracture be evaluated for child abuse.
Level of Evidence: II
Grade of Recommendation: A
This recommendation is addressed
by three level II studies. Two of these
studies reported that 14% and 12%
of the fractures were the result of
abuse in children aged 0 to 1 year
and 0 to 3 years, respectively.3,5 The
third study reported that only two
(2%) of the fractures were caused by
abuse among children aged 0 to 15
years, which would correspond to
13% if both of these fractures occurred in children aged 0 to 1 year.
The work group recognizes that
the most important elements in evaluating a child for abuse are a complete history and physical examination with attention paid to the signs
and symptoms of child abuse. The
work group defines evaluating a
child for abuse, however, as including not only these routine elements
but also direct communication with
the patients pediatrician or family
Recommendation 2
Treatment with a Pavlik harness or a
spica cast is an options for infants
aged 6 months with a diaphyseal femur fracture.
Level of Evidence: IV
Grade of Recommendation: C
Two studies addressed this recommendation. One retrospective comNovember 2009, Vol 17, No 11
Recommendation 3
We suggest early spica casting or
traction with delayed spica casting
for children aged 6 months to 5
years with a diaphyseal femur fracture with <2 cm of shortening.
Level of Evidence: II
Grade of Recommendation: B
Two level II studies and one level I
study addressed this recommendation.10-12 Based on the summary of
evidence, we did not find conclusive
evidence that one modality of treatment (spica casting or traction) was
superior, and no studies compared
flexible nails to either spica casting
or traction in this age group. We suggest using early spica casting over
Recommendation 4
We are unable to recommend for or
against early spica casting for children aged 6 months to 5 years with a
diaphyseal femur fracture with >2
cm of shortening.
Level of Evidence: V
Grade of Recommendation: I
Given that we found no studies
specifically addressing whether spica
casting should be utilized in this population or comparing spica casting
with other treatment modalities, we
can say only that the current available literature is insufficient to recommend for or against the use of
spica casting when >2 cm of femoral
shortening is present.
721
Recommendation 5
We are unable to recommend for or
against patient weight as a criterion
for the use of spica casting in children aged 6 months to 5 years with a
diaphyseal femur fracture.
Level of Evidence: V
Grade of Recommendation: I
We found no studies that specifically addressed weight as a criterion
for the use of spica casts in children.
The work group cannot determine
whether there is a maximum or minimum optimal weight range for the
use of spica casting.
Recommendation 6
When the spica cast is used in children aged 6 months to 5 years, altering the treatment plan is an option
when the fracture shortens >2 cm.
Level of Evidence: V
Grade of Recommendation: C
We found no data that addressed
the claim that >2 cm of shortening
during the follow-up of spica casting
for pediatric diaphyseal femur fracture should be addressed by changing the current treatmentfor example, exchanging or changing the cast
or moving to another treatment. Because of the potential harms associated with excessive femoral shortening, the consensus of the AAOS
work group is that altering the treatment plan is an option for treatment
in cases of excessive shortening. The
exact amount of shortening that may
cause potential harm is unclear.
Overgrowth of the injured femur is a
biologic response to fracture healing
in this age group that should be considered when making treatment decisions regarding shortening. Overgrowth can be variable in amount
and can occur for years after the
fracture has healed.
Recommendation 7
We are unable to recommend for or
against using any specific degree of
722
Recommendation 8
It is an option for physicians to use flexible intramedullary nailing to treat children aged 5 to 11 years diagnosed with
diaphyseal femur fractures.
Level of Evidence: III
Grade of Recommendation: C
One level I study,12 five level II
studies,14-18 and eight level III
studies19-26 addressed this recommendation. One level IV study27 addressed the issue of patient weight as
a criterion for the use of flexible nailing in this age group by comparing
the weight of patients with an excellent or satisfactory outcome to the
weight of patients with a poor outcome.
Recommendation 9
Rigid trochanteric entry nailing, submuscular plating, and flexible intramedullary nails are treatment options for children aged 11 years to
skeletal maturity with diaphyseal femur fractures, but piriformis or nearpiriformis entry rigid nailing is not a
treatment option.
Level of Evidence: IV
Grade of Recommendation: C
One level III and four level IV
studies addressed this recommendation. Skeletally immature patients are
at increased risk for osteonecrosis of
the femoral head when piriformis or
near-piriformis fossa entry nails are
used. The rate of this potentially devastating complication is at least
4%.28 Every effort should be made to
decrease the risk of osteonecrosis.
Heavier patients, as well as fracture patterns that compromise postreduction stability (ie, axial and/or
angular stability), may stimulate the
surgeon to choose rigid trochanteric
entry nailing or submuscular plating
over flexible intramedullary nailing.
One level IV study demonstrated a
five times higher risk of poor outcomes for flexible nailing in patients
weighing 49 kg (108 lb).27 In the
expert opinion of the work group,
external fixation is another option in
the older patient with an unstable
fracture pattern, but its significantly
higher complication rates, as demonstrated in other age groups,20,29 make
external fixation less desirable than
rigid trochanteric entry nailing or
submuscular plating. Again, we
found little evidence that compared
all options in a head-to-head fashion;
thus, flexible intramedullary nails,
rigid trochanteric entry nails, and
submuscular plating are all treatment
options in this recommendation.
Recommendation 10
We are unable to recommend for or
against removal of surgical implants
November 2009, Vol 17, No 11
Recommendation 11
We are unable to recommend for or
against outpatient physical therapy to
improve function after treatment of pediatric diaphyseal femur fractures.
Level of Evidence: V
Grade of Recommendation: I
We found no evidence addressing
the use of outpatient physical therapy as a means to improve patient
function after treatment for a pediatric diaphyseal femur fracture.
Recommendation 13
We are unable to recommend for or
against the use of locked versus nonlocked plates for fixation of pediatric
femur fractures.
Level of Evidence: IV
Grade of Recommendation: I
There are no comparative studies
investigating the use of locked and
nonlocked plates. One level IV study
in this guideline used nonlocked
plates for the treatment of comminuted femoral fractures but made no
comparison with other treatment
methods. In light of insufficient data,
the work group is unable to make a
recommendation.
Recommendation 14
Recommendation 12
Regional pain management is an option for patient comfort perioperatively.
Level of Evidence: IV
Grade of Recommendation: C
We identified one level III study34
of a hematoma block and one level
IV study35 of a femoral nerve block,
both of which were effective at reducing pain. In the expert opinion of
the work group, the risks associated
with regional pain management,
723
Future Research
The quality of scientific data regarding the management of femoral fractures in children is clearly lacking.
Of 14 recommendations in the clinical practice guideline, only 2 have
level I or level II evidence available.
Controversy exists regarding the
optimal management of pediatric
femoral fractures. A multitude of
treatment options exists, including
Pavlik harness, spica casting, traction, external fixation, flexible intramedullary nailing, rigid intramedullary nailing, and bridge plating.
Properly designed randomized clinical trials comparing treatment options are necessary to determine optimal treatment. These trials would
benefit from being multicenter trials
in terms of accrual of patients and
external validity.
Specific trials that would be helpful
include the following: (1) Delayed
spica casting versus immediate spica
casting for femoral fractures in children aged 6 months to 6 years. (2)
Flexible intramedullary nailing versus immediate spica casting for femoral fractures in children aged 5 to 6
years, and even in some children
aged <5 years. (3) External fixation
versus bridge plating versus elastic
nails versus rigid trochanteric nails
for femoral fractures with the potential for further shortening in children
aged 6 years to skeletal maturity. (4)
Flexible intramedullary nailing versus rigid intramedullary nailing versus bridge plating for femoral fractures in children aged 6 years to
skeletal maturity. Intermediate outcome measures are often used in
studies regarding pediatric femoral
724
fractures, such as radiographic parameters. Functional outcome measures and later development of osteoarthritis are difficult to measure and
have a long time course.
However, the relationship is not clear
between commonly accepted radiographic measures of malunion and
functional outcome or later development of problems. Further research to
validate accepted radiographic standards of malunion would be extremely
valuable. Also, the inclusion of family
function outcomes may improve recommendations for younger patients who
may undergo either intramedullary nailing or immediate spica casting.
References
11.
12.
13.
14.
15.
16.
1.
2.
3.
17.
18.
19.
20.
21.
22.
4.
5.
6.
7.
8.
9.
24.
25.
26.
27.
32.
28.
33.
29.
34.
35.
36.
30.
31.
725